Results 91 to 100 of about 25,648 (169)

Efficacy of venetoclax-obinutuzumab treatment in achieving remission of acquired von Willebrand syndrome in chronic lymphocytic leukemia. [PDF]

Ann Hematol
Morelli F, Linari S, Rapolla CM, Attanasio M, Salvianti F, Sanna A.   +5 more
europepmc   +1 more source

Does age matter? Optimizing AML treatment in older adults. [PDF]

Blood Adv
Lai C, Lin TL.
europepmc   +1 more source

Targeted Therapy in Acute Myeloid Leukemia: Current Approaches and Novel Directions. [PDF]

J Pers Med
Ko KH, Gelfer R, Wheat JC, Cai SF.
europepmc   +1 more source

Integrating Targeted Therapies into AML Frontline Therapy: Who Gets What and What Does the Future Hold? [PDF]

Cancers (Basel)
Schreiber J, Hopfinger G, Gleixner KV.
europepmc   +1 more source

FOXM1 inhibitor, RCM‑1, enhances venetoclax mediated apoptosis through downregulation of ATP2B4 in rhabdomyosarcoma. [PDF]

Int J Oncol
Merjaneh N, Lan YW, Deng Z, Donovan J, Wang G, Do J, Juan T, Xia X, Kalinichenko VV, Kalin TV.   +9 more
europepmc   +1 more source

Emerging therapeutics for the treatment of light chain and transthyretin amyloidosis [PDF]

, 2019
Lenihan, Daniel J, Stockerl-Goldstein, Keith E, Zhang, Kathleen W   +2 more
core   +1 more source

Milestones in Chronic Lymphocytic Leukemia [PDF]

, 2017

core   +1 more source

Venetoclax-based low-intensity therapy in pediatric AML: A viable option for chemotherapy-intolerant patients. [PDF]

Am J Blood Res
Dhariwal N, Srinivasan S.
europepmc   +1 more source

Impact of venetoclax trough levels on safety and efficacy in the treatment of acute myeloid leukemia. [PDF]

Sci Rep
Hayashi H, Yamagiwa T, Kanda J, Ishikawa T, Sawa M, Miyahara Y, Tachibana T, Watanabe M, Ueda Y, Tsutsumi Y, Imada K, Fujiwara SI, Toubai T, Yoshifuji K, Hirata H, Kawabata H, Tsuji M, Wakita S, Yokoyama H, Kitano T, Murai K, Kataoka Y, Kawata E, Kimura SI, Yamamoto R, Miyao K, Nakayama D, Izumi A, Kawata T, Onda Y, Sakamoto T, Mizumoto C, Kitawaki T, Yamashita K, Yonezawa A, Kawakami T, Nakagawa S, Taniguchi R, Terada T, Takaori-Kondo A.   +39 more
europepmc   +1 more source

Latest advances in frontline CLL treatment from the 2025 ASH congress. [PDF]

Ann Hematol
Visentin A.
europepmc   +1 more source